ArticleHepatology international2023
Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044.
Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychosocial therapy improves outcomes for alcohol use disorder in people with chronic liver disease: A systematic review and meta-analysis.Hepatology communications · 2025Pooled it
- Article
- Hepatitis virus seroconversion among patients on maintenance hemodialysis in North India: a prospective cohort study.Osong public health and research perspectives · 2026Article
- Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation.The Journal of biological chemistry · 2026Article
- [Histone deacetylases and alcohol-related liver disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Global disparities in liver cancer burden: an epidemiological and socioeconomic analysis using GBD 1990-2021 data.Discover oncology · 2026Article
- Alcohol-related cirrhosis mortality, 1990-2021: temporal trends and development-level inequalities.Gastroenterology and hepatology from bed to bench · 2026Article
- Dynamics of Fecal microRNAs Following Fecal Microbiota Transplantation in Alcohol-Related Cirrhosis.Journal of clinical medicine · 2025Article
- Analysis of burden of liver cancer by GBD 2021.Future science OA · 2025Article
- Global burden of liver cirrhosis: trends from 1990-2021 and projections to 2060.Journal of health, population, and nutrition · 2025Article
- Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030.Cancer medicine · 2025Article
- Global, regional, and national liver cancer attributable to smoking and alcohol use burden, 1990-2021: analysis for the global burden of disease 2021 study.BMC public health · 2025Article
- Current and emerging strategies for the prevention of hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2025Review
- The descriptive epidemiology and projection of liver cancer in adolescents and young adults: findings from the global burden of disease study 2021.Frontiers in medicine · 2025Article
- Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.PloS one · 2025Article
- Forecasting Alcohol-Related Liver Disease Mortality Trends in Younger Populations Using Advanced Time-Series Models: A 1999-2030 Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- 3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.The EPMA journal · 2024Article
- Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake.Journal of gastroenterology and hepatology · 2024Article
- Burden of alcohol use disorder and its consequences in Iran from 1990 to 2019: Findings from the global burden of disease study.Preventive medicine reports · 2024Article
- Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier.Hepatology international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIdentifying the temporal trends of cirrhosis and liver cancer attributable to alcohol use in both the past and the future can formulate the control strategies.
methodsData on cirrhosis and liver cancer attributable to alcohol use from 1990 to 2019, including mortality and disability-adjusted life year (DALY) rates were collected from the 2019 Global Burden of Disease (GBD) study. To analyze the temporal trends, the average annual percentage change (AAPC) was calculated, and the Bayesian age-period-cohort model was applied.
resultDeaths and DALY of cirrhosis and liver cancer attributable to alcohol use increased year by years, but the age-standardized death rate (ASDR) and age-standardized DALY rate declined or remained stable from 1990 to 2019 in most regions of the world. The burden of cirrhosis attributable to alcohol increased in low-middle social-development index (SDI) regions, while the burden of liver cancer increased in high-SDI regions. Eastern Europe and Central Asia have the highest burden of cirrhosis and liver cancer caused by alcohol use. Deaths and DALYs are mainly distributed in people aged 40+ years, but there is an increasing trend in people aged under 40 years. New deaths from cirrhosis and liver cancer attributable to alcohol use are predicted to increase in the next 25 years, but the ASDR of cirrhosis in males will increase slightly.
conclusionsAlthough the age-standardized rate of cirrhosis and liver cancer due to alcohol use have decreased, the absolute burden increased and will continue to increase. Therefore, alcohol control measures should be further strengthened and improved through effective national policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.